Biotech News

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

Revolution Medicines (RVMD)ir.revmed.com2026-05-07 06:01 ESTClinical readout

Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Revolution Medicines

Revolution Medicines is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

RVMDRevolution Medicines2026-05-31 16:16:35 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-05-22 00:08:27 EST

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

RVMDRevolution Medicines2026-05-07 00:12:25 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

RVMDRevolution Medicines2026-05-06 18:46:39 EST

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States